1876: Founded in Indianapolis, Indiana by Colonel Eli Lilly as Eli Lilly and Company; emphasized medicine quality, reliable formulation, and ethical marketing vs. “patent medicines”

1880s–1890s: Expanded product lines and manufacturing discipline; distribution grew beyond Indiana to an early national footprint

1895: Developed and industrialized gelatin-coated pills/capsules, improving dosing consistency and patient acceptance

Late 1890s–1900s: Increased focus on standardized production processes and early scientific approaches to drug development

1919: Established formal research capability, strengthening in-house science as a core strategy

1923: Scaled up and commercialized insulin (with University of Toronto collaboration), becoming a major global supplier and establishing leadership in biologic manufacturing

1920s: Expanded international reach and modernized production facilities to meet rising biologics demand

1930s: Continued industrial R&D and process innovation; strengthened quality systems and large-scale manufacturing

1940s (World War II period): Expanded antibiotics production, notably penicillin manufacturing, scaling output for military and civilian needs

1940s: Advanced fermentation and purification technologies, building expertise for later complex therapeutics

1950s: Broadened global operations and portfolio; invested in sophisticated chemistry, formulation, and clinical development

1960s: Built international commercial presence and diversified R&D across disease areas, positioning for later blockbuster era

1970s: Expanded centralized R&D and clinical trial infrastructure; increased focus on chronic diseases with large global populations

1982: Introduced recombinant human insulin (Humulin), among the first major genetically engineered medicines, reinforcing biotech-enabled leadership

1987: Launched Prozac (fluoxetine), defining SSRI antidepressant; drove major global growth and expanded marketing reach and psychiatry portfolio

1990s: Accelerated globalization of manufacturing and commercial operations

1990s: Expanded alliances and technology investments beyond small molecules, strengthening biotechnology capabilities

1996: Launched Zyprexa (olanzapine), reinforcing CNS leadership as a major global product

Early 2000s: Faced patent-cycle pressures; reshaped R&D productivity and prioritization

2005: Acquired Applied Molecular Evolution, boosting biologics discovery and protein engineering capabilities

2008: Acquired ImClone Systems, adding oncology assets and targeted cancer biologics expertise

2009: Acquired SGX Pharmaceuticals, strengthening structure-based discovery and oncology pipeline options

Early 2010s: Increased emphasis on specialty medicines, biologics, and advanced clinical development across diabetes and immunology

2014: Launched Trulicity (dulaglutide), GLP-1 therapy for type 2 diabetes, becoming a major growth driver

2016: Launched Taltz (ixekizumab) for psoriasis and related conditions, strengthening immunology leadership

2017: Acquired CoLucid Pharmaceuticals, expanding pain and migraine pipeline capabilities

2019: Verzenio (abemaciclib) approvals expanded in breast cancer, strengthening oncology profile

2010s focus sharpened around specialty biologics with breakout franchises in cardiometabolic disease, immunology, and oncology.

2020: Initiated major manufacturing expansions aligned to rising diabetes/obesity demand; advanced COVID-19 antibody efforts and rapid global supply coordination

2021: Donanemab late-stage program visibility increased (Alzheimer’s); strengthened neurology ambition via pivotal trials and regulatory engagement

2022: Launched Mounjaro (tirzepatide) for type 2 diabetes, dual GIP/GLP-1 agonist; rapidly became cornerstone product elevating global standing

2023: Approved Jaypirca (pirtobrutinib) in certain blood cancers, supporting oncology growth with next-generation targeted therapy

2023: Approved Ebglyss (lebrikizumab) in select markets for atopic dermatitis (regional timelines vary), expanding immunology

2023–2024: Approved Zepbound (tirzepatide) for chronic weight management (U.S.), cementing obesity pharmacotherapy leadership and driving global demand

2023–2024: Continued large-scale investments in new manufacturing sites and capacity expansions to secure global supply for incretin-based therapies

2024–Present: Continued progression across Alzheimer’s, oncology, immunology, and cardiometabolic pipelines; expanded international rollout of obesity and diabetes franchises, reinforcing leadership position